Clinical Trial Update: Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating toripalimab plus surgery versus surgery alone in resectable recurrent nasopharyngeal carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma, PD-1 | Phase 3 | Status: RECRUITING